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1. Introduction
  Diabetes mellitus (DM) consists of a group of syndromes 
characterized by hyperglycemia; altered metabolism of 
lipids, carbohydrates, and proteins; and an increased 
risk of complications[1]. Apart from currently available 
therapeutic options for diabetes like oral hypoglycemic 
agents and insulin, which have limitations of their own, 
many herbal medicines have been recommended for the 
treatment of diabetes[2]. A variety of ingredients present in 
medicinal plants are thought to act on a variety of targets 
by various modes and mechanisms. They have the potential 
to impart therapeutic effect in complicated disorders like 
diabetes and its complications[3]. Hence the present study 
was carried out to evaluate the antidiabetic activity of
Merremia tridentata (L.) Hall. f. (Family: Convolvulaceae) 
(M. tridentata) . 
  M. tridentata commonly known as “Mudiarkunthal” or 
“Savulikodi” or “Thrippan Pullu” in Tamil and “Prasarini” 
in Sanskrit is reported to possess a number of medicinal 
values[4]. It is a thick climbing herb with woody rootstock 
spreading on the walls and on the grounds. It grows in 
all plain districts of Tamilnadu, Western peninsula and 
Bengal[5]. The plant is considered bitter, astringent, 
tonic and it’s used in the treatment of rheumatism, piles, 
swellings and urinary disorders[4]. The previous studies 
conducted on M. tridentata showed strong wound healing, 
anti-inflammatory and anti-arthritic activities[6,7].  It is 
also used as a supplementary feed to the grass Panicum 
maximum for young West African Dwarf Sheep[8]. The 
aerial parts of the M. tridentata contain flavonoids, 
diosmetin, luteolin, and their 7-O-毬-D-glucosides[9]. 
Ergosine alkaloids have been isolated from the seeds of 
M. tridentata[10]. Pyrolidine alkaloids like hygrins and 
nicotine have been isolated from the root and the aerial 
parts of M. tridentata[10]. The acetone extract of root possess 
high phenolic contents and rich potential of antioxidant 
activity[11]. Moreover K. Arunachalam et al.[12] also 
revealed the HPTLC analysis of acetone extract of root has 
six phenolic and two flavonoid compounds existing. Bio-
flavonoids are well-known for their multi-directional 
biological activities including anti-diabetic efficacy[13]. 
Numerous studies have been carried out to explore their 
potential role in the treatment of diabetes[14]. Considering 
the medicinal potential of this plant, M. tridentata root was 
chosen for the study. 
Objective: To investigate the antidiabetic effect of aqueous extract of Merremia tridentata 
(M. tridentata) root (MTRAE) in normal, glucose-loaded hyperglycemic and streptozotocin (STZ)-
induced diabetic rats. Methods: Oral administration of MTRAE at the doses of 50, 100 and 150 
mg/kg was studied in normal, glucose-loaded and STZ-diabetic rats. The three doses caused 
significant reduction in blood glucose levels in all the models. Results: The effect was more 
pronounced in 100 and 150 mg/kg than 50 mg/kg. MTRAE also showed significant increase in 
serum insulin, body weight and glycogen content in liver and skeletal muscle of STZ-induced 
diabetic rats while there was significant reduction in the levels of serum triglyceride and total 
cholesterol. MTRAE also showed significant antilipidperoxidative effect in the pancreas of STZ-
induced diabetic rats. The antidiabetic effect of M. tridentata was compared with glibenclamide, 
a well known hypoglycemic drug. Conclusions: The results indicate that aqueous extract of M. 
tridentata root possesses significant antidiabetic activity.
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2. Materials and methods
2.1. Chemicals
  Streptozotocin was purchased from SISCO Research 
Laboratories Ltd., Mumbai. Glibenclamide was obtained 
as a gift sample from Sanofi Aventis India Ltd. All other 
chemicals and reagents used were of analytical grade. 
2. 2. Plant material and extraction
  M. tridentata was collected from Coimbatore, Tamil 
Nadu State, India during November 2008, authenticated 
and deposited in the Department of Botany Herbarium, 
Bharathiar University with voucher number BUBH‐2895. 
The freshly collected plant roots were washed thoroughly 
in tap water, shade dried at room temperature (25 曟) 
powdered, and it was macerated with distilled water for 48 h 
at room temperature with shaker. It was then filtered through 
Whatman filter paper. The filtrate was air dried and stored 
in refrigerator for further use as M. tridentata root aqueous 
extract (MTRAE). During experiment the crude extract was 
diluted with distilled water just before administration to 
animals.
2.3. Experimental animals
  Healthy adult male albino Wistar rats (150-200 g), 
in-house bred at the Animal House of Kovai Medical 
Centre Hospital College of Pharmacy, Coimbatore, Tamil 
Nadu, India were used for the study. Rats were housed 
in polypropylene cages lined with husk in standard 
environmental conditions [temperature (25依2) 曟, relative 
humidity (55依10)% and 12:12 light:dark cycle]. The rats 
were fed on a standard pellet diet (Amrut rat and mice feed, 
Sangli, India) ad libitum and had free access to water. The 
experimental protocol was subjected to the scrutiny of the 
Institutional Animal Ethics Committee and was cleared by 
the same before beginning the experiment (No. KMCRET/
M.Sc./4/2010-11). 
2.4. Experimental design
  Antidiabetic activity of MTRAE was assessed in normal, 
glucoseloaded hyperglycemic and streptozotocin-induced 
diabetic rats. In all studies, the animals were fasted 
overnight for 16 h with free access to water throughout the 
duration of the experiment.
2.4.1. Evaluation of extract on normal healthy rats 
  This study was carried out according to the method of Kar 
et al.[15]  At the end of the fasting period, taken as zero time 
(0 h), blood was withdrawn from the retro-orbital plexus of 
the eye under mild ether anesthesia. Serum was separated 
by centrifugation and glucose was estimated. The animals 
were then randomly divided into four groups of six animals 
each. Group I served as control and received distilled water. 
Groups II, III and IV received MTRAE orally at the dose of 
50, 100, 150 mg/kg. Blood glucose levels were determined 1, 
2, 3 and 4 h following treatment.
2.4.2. Evaluation of extract in oral glucose tolerance test[16]
  Healthy rats were divided into four groups of six animals 
each: Group I served as control received only vehicle 
(distilled water) and Groups II, III and IV received 
MTRAE orally at the dose level of 50, 100 and 150 mg/kg, 
respectively. All the animals were given glucose (2 g/kg) 
60 min after dosing. Blood samples were collected from 
the retro-orbital plexus of the eye just prior to (0 h) and at 
30, 60, 90 and 120 min after the glucose loading, and blood 
glucose levels were estimated. 
2.4.3. Evaluation of extract in streptozotocin-induced 
diabetic rats [17]
  Experimental  diabetes  was induced by s ingle 
intraperitoneal injection of 55 mg/kg of streptozotocin (STZ), 
freshly dissolved in cold citrate buffer, pH 4.5. Control 
animals received only citrate buffer. After 5 days of STZ 
injection, animals with fasting blood glucose above 250 mg/dL
were considered as diabetic and included in the study. 
The animals were randomly assigned into six groups of six 
animals each and received the following treatments: Group 
I: Normal control + distilled water, Group II: Diabetic + 
distilled water, Group III: Diabetic + MTRAE (50 mg/kg),
Group IV: Diabetic + MTRAE (100 mg/kg), Group V: 
Diabetic + MTRAE (150 mg/kg) and Group VI: Diabetic + 
glibenclamide (10 mg/kg). The freshly prepared solutions 
were orally administered daily for 21 days. Body weights and 
blood glucose analysis was done weekly on overnight fasted 
animals. At the end of the experimental period, the animals 
were fasted an overnight and blood was collected for various 
biochemical estimations. The animals were sacrificed 
by cervical decapitation. Organs like liver, pancreas and 
skeletal muscle were dissected out, immediately rinsed 
in ice cold saline and stored for further biochemical 
estimations.
2.4.4. Biochemical analysis
  Serum glucose analysis was done by GOD-POD method 
using Glucose Estimation Kit (Erba Diagnostics, India). 
Other serum estimations were done spectrophotometrically 
using standard kits available which included serum insulin 
(RIA kit provided by BRIT, BARC, India), serum triglycerides 
(GPO-Trinder method, Erba Diagnostics), and serum total 
cholesterol (CHOP-PAP method, Erba Diagnostics). Glycogen 
was estimated in liver and skeletal muscle by the method of 
Good et al[18]. In vivo lipid peroxidation, expressed as TBARS 
(thiobarbituric acid reactive substances) was estimated in 
the pancreatic tissue homogenate according to the method of 
Ohkawa et al.[19]
2.4.5. Acute oral toxicity study
  Acute oral toxicity of MTRAE was performed on Swiss 
female albino mice, according to OECD Guideline 423. Two 
groups of three mice each were used for the study. Group 
I served as control and received distilled water. Group 
II received single oral dose of MTRAE (2 000 mg/kg). The 
animals were observed for gross behavioral, neurological, 
autonomic and toxic effects at short intervals of time for 24 h 
and then daily for 14 days. Food consumption was monitored 
daily and body weights were recorded weekly. On 14th day, 
animals were sacrificed and all the organs were removed for 
gross pathological examination.
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2.5. Statistical analysis
  All values are expressed as mean±S.E.M. Statistical 
analysis was performed by one-way analysis of variance 
(ANOVA) followed by Tukey’s multiple comparison tests. The 
results were considered statistically significant if P < 0.05.
3. Results
3.1. Effect of MTRAE on normoglycemic rats
  Results of the effect of graded doses of MTRAE on blood 
glucose level of normal healthy rats are presented in 
Figure 1. MTRAE produced peak hypoglycemia at 3 h. Dose 
dependent blood glucose reduction was observed in animals 
treated with 50, 100 and 150 mg/kg (13.44%, 24.72% and 
26.2%, respectively). Blood glucose levels were restored in 
all treatment groups by 4h.
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Figure 1. Effect of MTRAE on blood glucose levels in normoglycemic 
rats. 
Each value is expressed as mean of six observations. *P < 0.05 when 
compared with values of 0h of the same group.
3.2. Effect of MTRAE on oral glucose tolerance in normal 
rats
  MTRAE, when administered 60 min. prior to glucose 
loading produced significant reduction (P<0.05) in the rise in 
blood glucose levels at 60 min. after glucose administration. 
MTRAE at doses of 50, 100 and 150 mg/kg produced 13.04%, 
20.15% and 14.36% reduction in blood glucose respectively 
when compared to vehicle treated group at 60 min (Figure 
2).
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Figure 2. Effect of MTRAE on oral glucose tolerance in rats. 
3.3. Effect of MTRAE on fasting blood glucose and body 
weight in STZ-induced diabetic rats
  The effect of repeated oral administration of MTRAE on 
blood glucose levels in STZ-diabetic rats is presented in 
Figure 3. MTRAE, administered at three different doses 
of 50, 100, 150 mg/kg to STZ-treated diabetic rats caused 
significant (P<0.001) reduction of blood glucose levels which 
was related to dose and duration of treatment. Maximum 
reduction was observed on day 21 (28.56%, 49.65% and 
48.58%, respectively). MTRAE 50 mg/kg exhibited maximum 
glucose lowering effect in diabetic rats compared to the 
other two doses. Glibenclamide exhibited 61.66% reduction 
in blood glucose levels at the end of the study when 
compared to diabetic control. STZ produced significant loss 
in body weight as compared to normal animals during the 
study. Diabetic control continued to lose weight till the end 
of the study while MTRAE at all the three doses (50, 100 and 
150 mg/kg) showed significant improvement (P<0.05) in body 
weight compared to diabetic control (Figure 4).
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Figure 3. Effect of MTRAE on blood glucose levels of STZ-induced 
diabetic rats. 
Each value is expressed as mean依S.E.M. (n = 6). aP< 0.001 when 
compared to corresponding values of the normal control. bP<0.001 
when compared to corresponding values of the diabetic control.
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Figure 4. Effect of MTRAE on body weight of STZ-induced diabetic 
rats. 
3.4. Effect of MTRAE on serum insulin in STZ-induced 
diabetic rats
  STZ caused a significant decrease in serum insulin. 
Administration of MTRAE at all the three doses (50, 100 and 
150 mg/kg) caused significant (P < 0.01) increase in insulin 
levels at the end of the study. Of the three doses, 50 mg/kg
showed maximum increase which was comparable to 
glibenclamide (Table 1).
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3.5. Effect of MTRAE on serum lipids in STZ-induced 
diabetic rats
  MTRAE showed a dose related significant (P< 0.01) 
reduction in triglycerides (13.91%, 22.62% and 25.11% 
for 50, 100 and 150 mg/kg, respectively) compared to 
pretreatment levels (Table 1). MTRAE at the doses of 100 and 
150 mg/kg was more effective than 50 mg/kg in reducing the 
cholesterol levels.
3.6. Effect of MTRAE on glycogen content in STZ-induced 
diabetic rats
  Glycogen content in liver and skeletal muscle decreased 
significantly (P<0.001) in diabetic control compared to 
normal control (Table 1). Administration of MTRAE at the 
doses of 100 and 150 mg/kg for 21 days resulted in significant 
(P<0.001) increase in the glycogen levels in both the liver 
and skeletal muscle. However, with none of the dose levels, 
the values were restored to normal.
3.7. Effect of MTRAE on pancreatic lipid peroxidation in 
STZ-induced diabetic rats
  There was a significant elevation in the level of TBARS in 
the diabetic control when compared with the corresponding 
normal control. However, the oral administration of MTRAE 
and glibenclamide tended to bring these values back to 
normal (Table 1).
3.8. Acute oral toxicity study
  In acute toxicity study, MTRAE treated animals did not 
show any change in their behavioral pattern. There was 
no significant difference in the body weights and food 
consumption when compared to the vehicle treated group. 
Also, no gross pathological changes were seen. Thus, it was 
concluded that MTRAE was safe at 2 000 mg/kg.
4. Discussion
  This study was undertaken to evaluate the hypoglycemic 
activity of MTRAE in normal, glucose-loaded hyperglycemic 
and streptozotocin-induced diabetic rats. In normoglycemic 
rats, MTRAE showed dose dependent hypoglycemic effect at
3 h. From OGTT it could be concluded that dose of 100 mg/kg
showed the maximum improvement in glucose tolerance. 
STZ significantly induced hyperglycemia accompanied 
by hypoinsulinemia. Oral administration of MTRAE for 21 
days caused a significant decrease in blood glucose levels. 
The possible mechanism by which MTRAE mediated its 
antidiabetic effect could be by potentiation of pancreatic 
secretion of insulin from existing 毬-cells of islets, as was 
evident by the significant increase in the level of insulin 
in the extract treated animals. The hypoglycemic activity 
of MTRAE was compared with glibenclamide, a standard 
hypoglycemic drug. From the results of the present study, 
it may be suggested that the mechanism of action of MTRAE 
may be similar to glibenclamide action. Diabetes mellitus 
impairs the normal capacity of the liver to synthesize 
glycogen. Synthase phosphatase activates glycogen synthase 
resulting in glycogenesis and this activation appears to be 
defective in diabetes[20]. Skeletal muscle is also a major site 
of insulin-stimulated glucose uptake[21]. Decrease in both 
muscle and hepatic glycogen was observed in this study. 
Treatment with MTRAE (100 and 150 mg/kg) for 21 days 
significantly increased muscle and liver glycogen indicating 
that the defective glycogen storage of the diabetic state was 
partially corrected by the extract. Hypercholesteremia and 
hypertriglyceridemia are primary factors involved in the 
development of atherosclerosis and coronary heart disease 
which are the secondary complications of diabetes[22]. 
MTRAE significantly reduced serum triglycerides and total 
cholesterol in STZ-diabetic rats. Thus, it is reasonable 
to conclude that MTRAE could modulate blood lipid 
abnormalities. In diabetes, tissue damage is considered 
to be mediated by free radicals by attacking membranes 
through peroxidation of unsaturated fatty acids[23-29]. Lipid 
peroxidation eventually leads to extensive membrane 
damage and dysfunction[30]. Decreased lipid peroxidation 
and improved antioxidant status may be one of the 
mechanisms by which drug treatment could contribute to the 
prevention of diabetic complications[31]. In our study, MTRAE 
significantly attenuated the increased lipid peroxidation 
which could be due to the antioxidant effect of flavonoids, 
detected in the preliminary phytochemical screening of the 
extract. Thus, the significant antidiabetic effect of MTRAE 
could be due to the presence of various phytoconstituents 
detected in the phytochemical screening which alone or in 
synergism can impart therapeutic effect.
  In conclusion, it can be stated, that the aqueous root 
Table 1
Effect of MTRAE on serum insulin, serum lipids, glycogen content in liver and skeletal muscle and lipid peroxidation in pancreas of STZ treated 
diabetic rats.
Experimental group
Serum insulin (U/mL)# Triglyceride (mg/dL)# Total cholesterol (mg/dL)#
Glycogen
(mg/g of wet tissue)#
TBARS (毺M/g
of wet tissue)#
Day 1 Day 21 Day 1 Day 21 Day 1 Day 21 Liver Skeletal muscle
Normal control 19.21依0.50 18.56依0.45   80.24依2.37   82.79依5.06   55.00依1.28   66.00依3.21 41.46依1.39 7.45依0.22 0.38依0.01
Diabetic control   8.57依0.26   6.01依0.34 162.10依6.62 218.11依7.69   95.00依2.38 139.47依5.93 14.31依1.03d 3.53依0.16d 0.64依0.02d
Diabetic+ MTAE(50 mg/kg)   8.34依0.42 10.81依0.38a,c 162.65依7.04 148.62依4.86a,c   97.99依2.34   88.11依2.75 20.85依1.00 4.09依0.13 0.54依0.01
Diabetic+ MTAE(100 mg/kg)   8.10依0.41 14.76依0.43a,c 162.10依6.15 133.245依7.59a,c   99.65依2.81   59.65依2.79b,c 28.73依1.14c 4.81依0.10c 0.46依0.01c
Diabetic+ MTAE(150 mg/kg)   8.14依0.45 14.85依0.55a,c 157.56依8.32 125.47依4.81a,c 100.43依1.53   60.50依3.79b,c 30.74依1.25c 4.69依0.11c 0.47依0.01c
Diabetic+ glibenclamide (10 mg/kg)   8.14依0.40 18.32依0.30a,c 158.01依7.45 102.41依3.51a,c   98.19依2.13   55.91依2.81b,c 32.58依0.96c 5.07依0.10c 0.41 依0.05c
# Each value is mean依S.E.M. (n = 6), a P < 0.01 when compared to the day 1 values of the same group, b P < 0.001 when compared to the day 1 
values of the same group, c P < 0.001 when compared to the corresponding values of the diabetic control, d P < 0.001 when compared with the 
corresponding values of the normal control.
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extract of M. tridentata has beneficial effects, in reducing 
the elevated blood glucose level and lipid profile of STZ-
induced-diabetic rats, but has no effect on normal rats. 
Thus, justifying the claim made by Ayurvedic classics. 
However, longer duration studies on chronic models are 
necessary to elucidate the exact mechanism of action so as 
to develop it as a potent antidiabetic drug.
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